Wells Fargo & Company Denali Therapeutics Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 64,783 shares of DNLI stock, worth $1.37 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,783
Previous 66,365
2.38%
Holding current value
$1.37 Million
Previous $1.42 Million
6.67%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding DNLI
# of Institutions
217Shares Held
115MCall Options Held
142KPut Options Held
90.3K-
Baillie Gifford & CO14MShares$297 Million0.23% of portfolio
-
Black Rock Inc. New York, NY12.2MShares$258 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$232 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.27MShares$175 Million0.03% of portfolio
-
State Street Corp Boston, MA6.32MShares$134 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.84B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...